General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0LCFYU
ADC Name
38751786 5D3 (CC-MLB8237)3.2-AF488
Synonyms
5D3 (CC-MLB8237)3.2-AF488 ADC
   Click to Show/Hide
Organization
The Johns Hopkins University School of Medicine; Johns Hopkins University; Institute of Biotechnology of the Czech Academy of Sciences; University Medical Center Utrecht.
Drug Status
Investigative
Drug-to-Antibody Ratio
3.2
Structure
Antibody Name
5D3 mAb-AF488
 Antibody Info 
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
 Antigen Info 
Payload Name
MLN8237
 Payload Info 
Therapeutic Target
Aurora kinase A (AURKA)
 Target Info 
Linker Name
NHS-PEG-TCO-Tz
 Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
The indication landscape of This ADC(2027 Update)
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
8.17
nM
CVCL_E9XK
Prostate carcinoma
Half Maximal inhibitory Concentration (lC50) 
161.9
nM
Undisclosed
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 8.17 nM Negative PSMA expression (PSMA-)
Method Description
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC3-PIP cells CVCL_E9XK
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 161.9 nM Positive PSMA expression (PSMA+++/++)
Method Description
The cytotoxicity of 5D3 (CC-MLN8237)3.2-AF488 was determined by treating PC3-PIP and PC3-Flu (control) cells in 96-well plates in RPMI 1640 culture media in the presence of 5D3- (CC-MLN8237)3.2-AF488 over a series of concentrations. Cells were seeded in a 96-well plate (2000 cells/well) and grown for 24 h to achieve 30%-40% confluency. Then, cells were treated with increasing concentrations of 5D3 (CC-MLN8237)3.2-AF488 or pure MLN8237 equivalent to the drug concentration in 5D3- (CC-MLN8237)3.2-AF555 (1.0 ng/mL-1.0 mg/mL by 10-fold increment). After the incubation for 72 h, IC50 values of 5D3 (CC-MLN8237)3.2-AF488 ATC and corresponding free MLN8237 were determined using the WST-8 assay (CCK-8 assay, Dojindo Molecular Technologies), following the manufacturer's protocol. Briefly, media in each well were replaced by 100 uL of the fresh media. Then, cells in each well were treated with 10 uL of WST-8 reagent and incubated at 37°C for 3 h. During incubation, WST-8 tetrazolium salt is reduced by dehydrogenase in living cells, forming a yellow formazan dye with λmax at 450 nm. After 3 h, the absorbance in wells was measured at 450 nm using a BioTek Epoch microplate spectrophotometer (Agilent Technologies). The concentration of the formazan dye in the media produced by dehydrogenases is directly proportional to the density of viable cells per well. The cell viability of treated cells was normalized to readings in untreated control cells with 100% viability. Data were fitted, and IC50 values for free MLN8237 and 5D3 (CC-MLN8237)3.2-AF488 were calculated using Prism 9 software (GraphPad, San Diego CA).

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC3-Flu cells Homo sapiens
References
Ref 1 Development and therapeutic evaluation of 5D3(CC-MLN8237)(3.2) antibody-theranostic conjugates for PSMA-positive prostate cancer therapy